Fortress Biotech, Inc. Total Liabilities and Equity
Fortress Biotech, Inc. (FBIO) had Total Liabilities and Equity of $316.71 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-13
- 2026-06-30: Liabilities and Equity $316.71M.
- 2026-03-31: Liabilities and Equity $356.87M.
- 2025-12-31: Liabilities and Equity $185.55M.
- 2025-09-30: Liabilities and Equity $181.41M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $316.71M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $356.87M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $185.55M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $181.41M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $159.90M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $178.07M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $144.22M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $127.08M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $145.69M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $164.65M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $167.53M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $150.55M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $180.72M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $263.55M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $294.30M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $323.56M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $363.95M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $407.93M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $396.50M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $407.83M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $418.16M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $391.04M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $333.41M 10-K · filed 2022-03-28 | $328.83M 10-K · filed 2021-03-31 |
| 2020-09-30 | $295.88M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $268.57M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $228.76M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $226.42M 10-K/A · filed 2021-04-09 | |
| 2019-09-30 | $221.59M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $227.26M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $200.54M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $140.99M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $224.92M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $236.87M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $265.07M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $245.95M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $245.09M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $249.85M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $211.91M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $170.73M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $145.42M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $98.06M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $104.91M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $118.61M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $86.86M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $83.70M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $90.45M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $89.33M 10-K · filed 2016-03-15 | $89.33M 10-K · filed 2015-03-16 |
| 2014-09-30 | $88.01M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $90.87M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $94.90M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $100.58M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $107.11M 10-Q · filed 2013-11-01 | |
| 2013-06-30 | $68.78M 10-Q · filed 2013-08-05 | |
| 2013-03-31 | $45.46M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $40.99M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $48.09M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $38.49M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $18.04M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $23.38M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $26.81M 10-Q · filed 2011-11-14 | |
| 2010-12-31 | $14.94M 10-K · filed 2012-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |